Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) Research & Development (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed Research & Development for 10 consecutive years, with $119298.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Research & Development fell 5.59% year-over-year to $119298.0, compared with a TTM value of $680079.0 through Sep 2025, down 57.52%, and an annual FY2024 reading of $933902.0, down 49.68% over the prior year.
  • Research & Development was $119298.0 for Q3 2025 at Sunshine Biopharma, down from $196232.0 in the prior quarter.
  • Across five years, Research & Development topped out at $816328.0 in Q4 2023 and bottomed at $41763.0 in Q4 2022.
  • Average Research & Development over 5 years is $252874.0, with a median of $215277.0 recorded in 2025.
  • The sharpest move saw Research & Development skyrocketed 5177.66% in 2021, then plummeted 81.71% in 2024.
  • Year by year, Research & Development stood at $91198.0 in 2021, then plummeted by 54.21% to $41763.0 in 2022, then surged by 1854.67% to $816328.0 in 2023, then tumbled by 81.71% to $149272.0 in 2024, then decreased by 20.08% to $119298.0 in 2025.
  • Business Quant data shows Research & Development for SBFM at $119298.0 in Q3 2025, $196232.0 in Q2 2025, and $215277.0 in Q1 2025.